- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01885182
Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain
A Phase III, Randomized, Double-blind, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxy/Nal Prolonged Release Tablets Compared to Oxy PR in Subjects With Moderate to Severe, Chronic Cancer Pain
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100142
- Beijing Cancer Hospital
-
Beijing, China, 100191
- Peking University Third Hospital
-
Beijing, China, 100005
- Beijing Hospital
-
Beijing, China, 100071
- 307th hospital of Chinese People's medical sciences
-
Beijing, China, 100700
- General Hospital of Beijing Military
-
Beijing, China, 100730
- Pejing Union Medical College Hospital
-
Beijing, China
- Beijing Friendship Hospital
-
Shanghai, China, 200080
- The First People's Hospital of Shanghai
-
Shanghai, China, 200233
- The Sixth Hospital of Shanghai
-
Tianjin, China, 300060
- Tianjin Cancer Hospital
-
-
Fujian
-
Fuzhou, Fujian, China
- Fujian Medical University Union Hospital
-
Fuzhou, Fujian, China, 350025
- Fuzhou General Hospital of Nanjing Military Command of PLA
-
Xiamen, Fujian, China
- The First Affiliated Hospital of Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Sun Yat-Sen Univercity Cancer Center
-
-
Hebei
-
Shijiazhuang, Hebei, China, 110001
- HeBei Medical University Fouth Hospital
-
-
Heilongjiang
-
Harbin, Heilongjiang, China
- Harbin Cancer Hospital
-
-
Henan
-
Xinxiang, Henan, China, 453100
- The First Affiliated Hospital of Xinxiang Medical University
-
-
Hubei
-
Changsha, Hubei, China, 430079
- Hubei Cancer Hospital
-
Wuhan, Hubei, China, 430030
- Tongji Hospital Tongji Medical College of HUST
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210000
- Jiangsu Cancer Hospital
-
Nanjing, Jiangsu, China, 310013
- The Second Hospital of Nanjing Medical University
-
-
Jilin
-
Changchun, Jilin, China
- Jilin Cancer Hospital
-
-
Liaoning
-
Dalian, Liaoning, China, 116023
- The Second Affiliated Hospital of Dalian Medical University
-
Shenyang, Liaoning, China, 110001
- The First Hospital of China Medical University
-
-
Shandong
-
Jinan, Shandong, China, 250013
- The Central Hospital of Jinan
-
-
Shanghai
-
Shanghai, Shanghai, China, 200003
- Shanghai Changzheng Hospital
-
-
Shanxi
-
Xi'an, Shanxi, China, 710032
- Tangdu hospital,fourth military medical university
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Sir Run Run Shaw Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Males & females, at least 18 years or older with a diagnosis of cancer.
Females less than one year post-menopausal must have a negative urine pregnancy test recorded prior to the first dose of study medication, be non-lactating, & willing to use adequate & highly effective method of contraception throughout the study. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (hormonal), sexual abstinence or vasectomised partner.
Subjects who are receiving WHO step II or Step III analgesic medication who have constipation induced, or worsened by their opioid medication, as shown by
- the subject's medical need of regular intake of laxatives to have at least 3 bowel evacuations per week, or having less than 3 bowel evacuations when not taking a laxative, respectively.
- the subject's self-assessment that their constipation was induced or worsened by their current pre-study opioid medication.
Documented history of moderate to severe, chronic cancer pain that requires around the-clock opioid therapy (starting dose of oxycodone PR between 20-80 mg/day) & are likely to benefit from WHO step III opioid therapy for the duration of the study. Subjects must be willing to discontinue their current opioid analgesic routine.
Opioid medication continue at a stable or nearly stable dose in the investigator's opinion during the treatment.
Subjects are willing to discontinue pre study laxative medication & take study specific laxative medication.
Subjects taking daily fibre supplementation or bulking agents are eligible if they can be maintained on a stable dose & regimen throughout the study, & in the investigators opinion are willing & able to maintain adequate hydration.
Subjects willing & able (e.g. mental & physical condition) to participate in all aspects of the study, including use of medication, completion of subjective evaluations, attending scheduled clinic visits, completing telephone contacts, & compliance with protocol requirements as evidenced by providing written, informed consent.
Subjects already taking non-opioid analgesics & all other concomitant medications (including those for the treatment of depression) are eligible to take part in the study. However, all concomitant medications that are considered necessary for the subject's welfare should be continued at a stable dose throughout the double-blind phase of the study & under the supervision of the investigator.
Expected survival time > 3 months.
With capability of reading, understanding & signing inform consent form & compliance with protocol requirements.
Exclusion Criteria Subjects that require a dose >80 mg/day oxycodone PR at the start of the double-blind phase.
Any history of hypersensitivity to oxycodone, naloxone, morphine, bisacodyl, related products & other ingredients.
Subjects with any situation in which opioids are contra-indicated, severe respiratory depression with hypoxia & or hypercapnia, severe chronic obstructive pulmonary disease, cor pulmonal, severe bronchial asthma, paralytic ileus.
Subjects with evidence of clinically significant gastrointestinal disease (e.g. paralytic ileus, peritoneal carcinosis), significant structural abnormalities of the gastrointestinal tract (e.g. scarring, obstruction etc) either related or not related to the underlying cancer or disease progression.
Evidence of clinically significant cardiovascular, renal, hepatic or psychiatric disease, as determined by medical history, clinical laboratory tests, ECG results & physical examination, that would place the subject at risk upon exposure to the study medication or that may confound the analysis & or interpretation of the study results.
Abnormal aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT; SGPT), r-glutamyltransferase (GGT) or alkaline phosphatase levels (>3 times the upper limit of normal) or an abnormal total bilirubin & or creatinine level(s) (greater than 1.5 times the upper limit of normal).
Cyclic chemotherapy in the two weeks before the screening visit or planned during the core study that has shown in the past to influence bowel function. If subjects are having their first cycle of chemotherapy during the 2 weeks before the screening visit or during the double-blind phase of the study they should be excluded from the study.
Radiotherapy that, in the investigators opinion, would influence bowel function or pain during the double-blind phase of the study.
Subjects with known or suspected unstable brain metastases or spinal cord compression that may require changes in steroid treatment throughout the duration of the study.
Subjects with uncontrolled seizures.
Subjects with increased intracranial pressure.
In the investigator's opinion, subjects who are receiving hypnotics or other central nervous system (CNS) depressants that may pose a risk of additional CNS depression with opioid study medication.
Subjects with myxoedema, not adequately treated hypothyroidism or Addisons disease.
Subjects who have a confirmed diagnosis of ongoing irritable bowel syndrome(IBS).
Surgery completed within 4 weeks prior to the start of the Screening Period, or planned surgery during the study that would influence pain or bowel function during the study or preclude completion of the study.
Subjects receiving opioid substitution therapy for opioid addiction (e.g. methadone or buprenorphine).
Active alcohol or drug abuse & or history of opioid abuse.
Subjects suffering from diarrhoea & or opioid withdrawal.
Subjects presently taking, or who have taken, naloxone ≤30 days prior to the start of the Screening Period.
Subjects who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days of study entry (defined as the start of the Screening Period), unless the subject is on data collection phase for Overall Survival.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oxycodone/Naloxone
5/2.5mg, 10/5mg, 20/10mg or 40/20mg
|
Other Names:
|
Active Comparator: Oxycodone
5mg, 10mg, 20mg or 40mg
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Change of BFI-Bowel Function Index at visit8
Time Frame: Visit8, visit8 taking place at week 4 or after early discontinuation/withdrawal from study
|
BFI is the mean of NAS for the following items:
|
Visit8, visit8 taking place at week 4 or after early discontinuation/withdrawal from study
|
The Change of BPI-SF at visit8
Time Frame: Visit8, visit8 taking place at week 4 or after early discontinuation/withdrawal from study
|
Brief pain inventory short-form(BPI-SF) recorded at final visit assesses subject's average pain over the last 24 hours.
score range is 0(no pain)-10(pain as bad as you can imagine).Do higher values represent a worse outcome.
|
Visit8, visit8 taking place at week 4 or after early discontinuation/withdrawal from study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Change of Symptoms of Constipation Based on Laxative Use From visit5 to visit8
Time Frame: visit 5 (week 1) to visit8 (week 4 or early discontinue/withdrawal from study)
|
At Visit 5(day7) and visit8(day28) number of bisacodyl taken(Number of laxative tablets took during the last 7 days (per week) and Daily number of laxative tablets took during the last 7 days (per day)*) for OXN PR and OXY PR groups.
|
visit 5 (week 1) to visit8 (week 4 or early discontinue/withdrawal from study)
|
The Change of Rescue Medication Use From visit5 to visit8
Time Frame: visit 5 (week 1) to visit8 (week 4 or early discontinue/withdrawal from study)
|
The average daily dose of rescue medication (Morphine Sulfate Tablet) for OXN PR group and OXY PR group at Visit 5(first week of double blind) and at Visit 8(last week of double blind).
|
visit 5 (week 1) to visit8 (week 4 or early discontinue/withdrawal from study)
|
The Change of Modified Subjective Opiate Withdrawal Scale (SOWS) From Visit1 to visit3,visit1 to visit9
Time Frame: Visit1(screening visit) to visit3 (day 1), visit1(screening visit) to visit9 (week 5)
|
to compare the Modified SOWS's Change from Visit 1(day-10-0) to Visit 3(day1),Change from Visit 1 to Visit 9(day35).The SOWS was scored as the total of the 15 symptoms.
each symptoms score is 0(not at all)-4(extremely).total score range is 0-60.Do higher values represent a better outcome.
|
Visit1(screening visit) to visit3 (day 1), visit1(screening visit) to visit9 (week 5)
|
To Assess Quality of Life Based on EQ-5D
Time Frame: Visit1(screening visit) to Visit8 (week 4 or after early discontinuation/withdrawal from study)
|
To assess quality of life based on EQ-5D by subjects evaluation via patient dairy.the
quality of life based on EQ-5D at Visit1 (day-10-0) and end of treatment Visit8(day28).
The scarc range is 0(the best state you can imagine)-100(the worst state you can imagine).Do higher values represent a worse outcome.
|
Visit1(screening visit) to Visit8 (week 4 or after early discontinuation/withdrawal from study)
|
The Change of Individual Items in BPI-SF(Except for Pain in Average) by Visit
Time Frame: visit2 (day 0) to visit8 (week 4 or early discontinue/withdrawal from study)
|
To compare the change of Brief pain inventory short-form (BPI-SF) 11 indivial items (except for pain in average) at visit2(day0) ,visit5(day7),visit6(day14),visit7(day21), visit8(day28).
each item range (except for how much relief from treatment /medication last 24hours is 0-100%,do higher values represent a better outcome.) is 0-10, do higher values represent a worse outcome.
|
visit2 (day 0) to visit8 (week 4 or early discontinue/withdrawal from study)
|
The Change of Bowel Movement by Visit
Time Frame: visit2 (day 0) to visit8 (week 4 or early discontinue/withdrawal from study)
|
Number pf bowel movements(BM) and number of days the subjects had a bowel movement in the last 7 days before the study visit will be summarized at visit2(day0) ,visit5(day7),visit6(day14),visit7(day21), visit8(day28)..
|
visit2 (day 0) to visit8 (week 4 or early discontinue/withdrawal from study)
|
The Chage of Symptoms of Constipation Based on Laxative Use From visit5 to visit8
Time Frame: visit 5 taking place at week 1 to visit8 taking place at week 4 or early discontinue/withdrawal from study where applicable
|
At Visit5(day7) and visit8(day28) number of bisacodyl taken(Number of laxative tablets took during the last 7 days (per week) and Daily number of laxative tablets took during the last 7 days (per day)*) for OXN PR and OXY PR groups
|
visit 5 taking place at week 1 to visit8 taking place at week 4 or early discontinue/withdrawal from study where applicable
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OXN10-CN-303
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on Oxycodone
-
Poznan University of Medical SciencesCompleted
-
Mount Carmel Health SystemWithdrawnPost-operative Pain ControlUnited States
-
Sharon WalshNational Institute on Drug Abuse (NIDA); Merck Sharp & Dohme LLCCompleted
-
Grünenthal GmbHCompleted
-
Yong-Hee ParkChung-Ang UniversityCompletedBlood Pressure | Intubation ComplicationKorea, Republic of
-
Seoul National University HospitalWithdrawnPainKorea, Republic of
-
Egalet LtdCompletedModerate-to-severe Chronic Low Back PainUnited States
-
Seoul National University HospitalCompleted
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Opioid-Related DisordersUnited States